Guidance, NICE advice and quality standards in development

Showing 41 to 50 of 402

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Avelumab for previously treated platinum-resistant ovarian cancer ID1497	Technology appraisal guidance	TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]	Technology appraisal guidance	TBC
Bed frames for patient care and recovery in acute clinical settings: late stage assessment (provisional title)	Health technology evaluation	28 May 2025
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]	Technology appraisal guidance	TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]	Technology appraisal guidance	TBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212	Technology appraisal guidance	5 March 2025
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211	Technology appraisal guidance	19 March 2025
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]	Technology appraisal guidance	TBC
Belzutifan for treating tumours associated with von Hippel-Lindau disease [ID3932]	Technology appraisal guidance	TBC
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]	Technology appraisal guidance	TBC